pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

President Trump nominates White House aide Heidi Overton as FDA Commissioner

Aug 19, 2026·read at raps ↗RegulatoryNeutral

President Donald Trump announced on his Truth Social platform that Heidi Overton, a White House aide, will be nominated to lead the U.S. Food and Drug Administration.

Overton is set to replace Marty Makary, who departed the agency in May. The nomination will now move to the Senate for confirmation.

The appointment signals the administration’s continued involvement in FDA leadership, though the article does not detail policy implications.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Trump taps Heidi Overton as next FDA Commissioner”

read at raps ↗
73 words · retrieved 3h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2d agoRecon: FDA releases draft guidance on gen AI-enabled devices; Industry warns Germany must reform drug pricingraps
  • 2d agoStudy highlights difficulty of measuring non-clinical factors that could influence FDA drug approval decisionsraps
  • 2d agoFDA issues draft guidance clarifying differences between ANDAs and 505(b)(2) applicationsraps
  • 2d agoStudy highlights limits of premarket evaluation for identifying recalls of high-risk medical devicesraps
  • 2d agoStakeholders call for flexibility in guidance aimed at reducing animal testing for cancer drugsraps